Cited by 384Microtubule and mitosis dynamicsCancer Treatment and PharmacologyHeterocyclic Compound Synthesis and Bioactivity

The DOI matches its Crossref record.

Taxanes: Microtubule and Centrosome Targets, and Cell Cycle Dependent Mechanisms of Action

Abal, M., Andreu, J., Barasoain, I.·2003·Current Cancer Drug Targets

DOI 10.2174/1568009033481967

Open this paper in CoChat — free account

Abstract

Microtubules are highly dynamic cellular polymers made of alphabeta-tubulin and associated proteins. They play a key role during mitosis, participating in the exact organization and function of the spindle, and are critical for assuring the integrity of the segregated DNA. Therefore, they represent one of the more effective targets in current cancer therapy. Paclitaxel (Taxol) is the prototype of the taxane family of antitumor drugs, and it was the first natural product shown to stabilize microtubules. This unique mechanism of action is in contrast to other microtubule poisons, such as Vinca alkaloids, colchicine, and cryptophycines, which inhibit tubulin polymerization. Taxanes block cell cycle progression through centrosomal impairment, induction of abnormal spindles and suppression of spindle microtubule dynamics. Triggering of apoptosis by aberrant mitosis or by subsequent multinucleated G1-like state related to mitotic slippage, depends on cell type and drug schedule. The development of fluorescent derivatives of paclitaxel led us to locate spindle pole microtubules and centrosomes as main sub-cellular targets of cytotoxic taxoids in living cells. In this review we discuss these findings in the context of a cell cycle-dependent response to taxanes, based on the cellular targets, and the status of the implicated cell cycle checkpoints. We also review those events that can influence this response, like the different signal transduction pathways activated/inactivated in relation to Bcl-2 phosphorylation and induction of apoptosis, and the controversial role of the p53 status on cell sensitivity to paclitaxel. Finally, cell cycle-dependent resistance, an emerging concept in combination sequential chemotherapy, is discussed on the basis of the cell cycle-dependent mechanisms of action of taxanes.

Integrity signals

Registry

Crossref · 10.2174/1568009033481967

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 101–200 of 384

Benzothienoquinazolinones as new multi-target scaffolds: Dual inhibition of human Topoisomerase I and tubulin polymerization
Ceramella, J., Caruso, A., Occhiuzzi, M. A., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111583 · Cited by 44
Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics
Xiao, Z., Xue, J., Semizarov, D., Sowin, T. J., Rosenberg, S. H., & Zhang, H. (2005) · International Journal of Cancer · doi:10.1002/ijc.20770 · Cited by 44
“It induces the spindle checkpoint through suppression of spindle microtubule dynamics by binding to the b-subunit of tubulin and stabilizing microtubules.(4,5) The resultant mitotic arrest will trigger rapid onset of p53-independent apoptotic pathway.”
Background
Inactivation of Id‐1 in prostate cancer cells: A potential therapeutic target in inducing chemosensitization to taxol through activation of JNK pathway
Zhang, X., Ling, M., Wang, X., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21592 · Cited by 44
“It is well established that taxol interferes with microtubules and induces G2/M arrest, which in turn, triggers apoptosis.(21,22) However, G2/M-independent apoptosis has also been reported.”
Background
Synergism between the Anticancer Actions of 2-Methoxyestradiol and Microtubule-Disrupting Agents in Human Breast Cancer
Han, G., Liu, Z., Shimoi, K., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.387.65.2 · Cited by 43
Photodynamic therapy induced cell cycle arrest and cancer cell synchronization: review
Moloudi, K., Abrahamse, H., & George, B. P. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1225694 · Cited by 45
A Systematic Review on Antitumor Agents with 1, 3, 5-triazines
Liu, B. (2015) · Medicinal Chemistry · doi:10.4172/2161-0444.1000255 · Cited by 42
“Although the range of antimitotic agent is extremely large, only few agents received clinical and commercial success up to present [134-139].”
Background
Formulation of Acid-Sensitive Micelles for Delivery of Cabazitaxel into Prostate Cancer Cells
Aydin, Ö. F., Youssef, I., Durmaz, Y. Y., Tiruchinapally, G., & ElSayed, M. E. H. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00147 · Cited by 42
PDMP sensitizes neuroblastoma to paclitaxel by inducing aberrant cell cycle progression leading to hyperploidy
Dijkhuis, A., Klappe, K., Jacobs, S. C., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0457 · Cited by 42
“At high paclitaxel concentrations, bipolar spindle formation is affected possibly due to an additional effect of paclitaxel on centrosome function (3).”
Background
Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach
Tulsyan, S., Chaturvedi, P. K., Singh, A. K., et al. (2014) · Gene · doi:10.1016/j.gene.2014.04.004 · Cited by 41
“Paclitaxel and docetaxel — the two common taxanes interfere with themicrotubules at themitotic spindle, resulting in cell cycle arrest duringmitosis and finally cell death (Abal et al., 2003).”
Background
Localized delivery of immunotherapy via implantable scaffolds for breast cancer treatment
Hope, A., Wade, S. J., Aghmesheh, M., & Vine, K. L. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.043 · Cited by 40
The Role of α1-Adrenoceptor Antagonists in the Treatment of Prostate and Other Cancers
Batty, M., Pugh, R., Rathinam, I., Simmonds, J. B., Walker, E., Forbes, A., Anoopkumar‐Dukie, S., McDermott, C., Spencer, B. H., Christie, D., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081339 · Cited by 41
Withaferin-A induces apoptosis in osteosarcoma U2OS cell line via generation of ROS and disruption of mitochondrial membrane potential
Zhang, H., & Zhang, H.-L. (2017) · Pharmacognosy Magazine · doi:10.4103/0973-1296.211042 · Cited by 40
Noscapine induces apoptosis in human glioma cells by an apoptosis-inducing factor-dependent pathway
Newcomb, E. W., Lukyanov, Y., Smirnova, I., Schnee, T., & Zagzag, D. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3282ffd68d · Cited by 42
TACC3 depletion sensitizes to paclitaxel-induced cell death and overrides p21WAF-mediated cell cycle arrest
Schneider, L. X., Eßmann, F., Kletke, A., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210628 · Cited by 40
“Nevertheless, resistance and a decreased sensitivity to paclitaxel represent an emerging problem in chemotherapy (Abal et al., 2003).”
Pharicin A, a novel natural ent-kaurene diterpenoid, induces mitotic arrest and mitotic catastrophe of cancer cells by interfering with BubR1 function
Xu, H., Huang, Y., Wu, Y., Zhao, Y., Xiao, W., Lin, Q., Sun, H., Dai, W. H., & Chen, G. (2010) · Cell Cycle · doi:10.4161/cc.9.14.12406 · Cited by 39
“Paclitaxel and related taxanes exhibit potent anticancer activities by promoting tubulin polymerization and microtubule stabilization, which is followed by mitotic arrest and apoptosis.(3,4) These compounds are effective against a wide array of malignancies including refractory ovarian cancer, metastatic breast cancer…”
Background
Chemoresistance and targeting of growth factors/cytokines signalling pathways: towards the development of effective therapeutic strategy for endometrial cancer.
Guo, F., Zhang, H., Jia, Z., Cui, M., & Tian, J. (2018) · Europe PMC (PubMed Central) · Cited by 38
Synthesis, biological evaluation and mechanism study of chalcone analogues as novel anti-cancer agents
Chen, J., Yan, J., Hu, J., et al. (2015) · RSC Advances · doi:10.1039/c5ra14888j · Cited by 37
A synergistic combination therapy with paclitaxel and doxorubicin loaded micellar nanoparticles
Wang, Y., Ma, S., Xie, Z., & Zhang, H. (2014) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2013.12.051 · Cited by 37
Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes.
Kurebayashi, J., Yamamoto, Y., Kurosumi, M., Okubo, S., Nomura, T., Tanaka, K., & Sonoo, H. (2006) · PubMed · Cited by 37
Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells
Stordal, B., Davey, M. W., & Davey, R. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0148-7 · Cited by 36
“Taxanes bind to and stabilise microtubules and block cell cycle progression through centrosomal impairment, induction of abnormal spindles and suppression of spindle microtubule dynamics [53].”
Background
Cardiac glycosides inhibit cancer through Na/K-ATPase-dependent cell death induction
Geng, X., Wang, F., Tian, D., Huang, L., Streator, E. S., Zhu, J., Kurihara, H., He, R., Yao, X., Zhang, Y., et al. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114226 · Cited by 36
Design and synthesis of pironetin analogues with simplified structure and study of their interactions with microtubules
Marco, J. A., García-Pla, J., Cardá, M., Murga, J., Falomir, E., Trigili, C., Notararigo, S., Díaz, J. F., & Barasoaı́n, I. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.02.011 · Cited by 35
Self-citation
Arsenite-induced mitotic death involves stress response and is independent of tubulin polymerization
Taylor, B. F., McNeely, S., Miller, H. L., et al. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2008.02.030 · Cited by 35
“It has been reported that paclitaxel's induction of apoptosis canoccurdue to aberrantmitosis or to enteringamultinucleatedG1-like state subsequent to mitotic slippage, depending on cell type and drug schedule (Abal et al., 2003).”
Background
Taxane Refractory Prostate Cancer
Mathew, P. F., & DiPaola, R. S. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.04.032 · Cited by 35
Inhibition of microtubule dynamics impedes repair of kidney ischemia/reperfusion injury and increases fibrosis
Han, S. J., Kim, J.-H., Kim, J. I., & Park, K. M. (2016) · Scientific Reports · doi:10.1038/srep27775 · Cited by 33
Myc Prevents Apoptosis and Enhances Endoreduplication Induced by Paclitaxel
Gatti, G., Maresca, G., Natoli, M., Florenzano, F., Nicolin, A., Felsani, A., & D’Agnano, I. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005442 · Cited by 37
“To activate apoptosis in these phases of cell cycle, we used PTX, a drug that induces suppression of spindle microtubule dynamics and inhibits mitosis occurrence [35].”
BackgroundMethodInfluential
Schedule Dependent Efficacy of Gefitinib and Docetaxel for Bladder Cancer
Kassouf, W., Luongo, T., Brown, G. A., et al. (2006) · The Journal of Urology · doi:10.1016/j.juro.2006.03.072 · Cited by 34
Potential role of HIF-1-responsive microRNA210/HIF3 axis on gemcitabine resistance in cholangiocarcinoma cells
Silakit, R., Kittirat, Y., Thongchot, S., Loilome, W., Techasen, A., Ungarreevittaya, P., Khuntikeo, N., Yongvanit, P., Yang, J. H., Kim, N. H., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199827 · Cited by 34
A comprehensive review on novel targeted therapy methods and nanotechnology-based gene delivery systems in melanoma
Rahimi, A., Esmaeili, Y., Dana, N., Dabiri, A., Rahimmanesh, I., Jandaghian, S., Vaseghi, G., Shariati, L., Zarrabi, A., Javanmard, S. H., et al. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106476 · Cited by 36
Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents
Wang, R. C., Chen, X., Parissenti, A. M., Joy, A. A., Tuszyński, J. A., Brindley, D. N., & Wang, Z. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182400 · Cited by 33
Plasma polymerized nanoparticles effectively deliver dual siRNA and drug therapy in vivo
Michael, P. L., Lam, Y. T., Filipe, E. C., Tan, R. P., Chan, A., Lee, B. S. L., Feng, N., Hung, J., Cox, T. R., Santos, M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-69591-x · Cited by 32
Novel FOXM1 inhibitor identified via gene network analysis induces autophagic FOXM1 degradation to overcome chemoresistance of human cancer cells
Chesnokov, M. S., Halasi, M., Borhani, S., Arbieva, Z. H., Shah, B. N., Oerlemans, R., Khan, I., Camacho, C. J., & Gartel, A. L. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03978-0 · Cited by 35
Pegylation of Nanoliposomal Paclitaxel Enhances its Efficacy in Breast Cancer
Esfahani, M. K. M., Alavi, S. E., Akbarzadeh, A., Ghassemi, S., Saffari, Z., Zarabi, M. F., & Chiani, M. (2014) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v13i8.1 · Cited by 32
“It belongs to taxanes family of anti-tumor activity [7,8].”
Background
Ubiquitin-specific protease 7 is a druggable target that is essential for pancreatic cancer growth and chemoresistance
Chen, H., Zhu, X., Sun, R., Ma, P., Zhang, E., Wang, Z., Fan, Y., Zhou, G.-X., & Mao, R. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00951-0 · Cited by 32
“Cisplatin, oxaliplatin, paclitaxel, docetaxel, leucovorin, oxaliplatin and irinotecan are other commonly used drugs for PDAC therapy [23, 24].”
Background
Bioactive Molecules of Endophytic Fungi and Their Potential in Anticancer Drug Development
Kumar, S., Aharwal, R. P., Jain, R., et al. (2021) · Current Pharmacology Reports · doi:10.1007/s40495-021-00251-y · Cited by 32
A Comprehensive RNA Study to Identify circRNA and miRNA Biomarkers for Docetaxel Resistance in Breast Cancer
Huang, P., Li, F., Mo, Z., Geng, C., Wen, F., Zhang, C., Guo, J., Wu, S., Li, L., Brünner, N., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.669270 · Cited by 31
The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells
Demeule, M., Charfi, C., Currie, J.-C., Zgheib, A., Danalache, B. A., Béliveau, R., Marsolais, C., & Annabi, B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091910 · Cited by 33
Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment.
Ai, B., Bie, Z., Zhang, S., et al. (2016) · PubMed · Cited by 31
Design, synthesis, and biological evaluation of novel combretastatin A-4 thio derivatives as microtubule targeting agents
Stefański, T., Mikstacka, R., Kurczab, R., Dutkiewicz, Z., Kucińska, M., Murias, M., Zielińska‐Przyjemska, M., Cichocki, M., Teubert, A., Kaczmarek, M., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.050 · Cited by 32
Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers
McFadden, M., Singh, S. K., Oprea‐Ilies, G., & Singh, R. (2021) · Cancers · doi:10.3390/cancers13215480 · Cited by 32
A Phase Ib and Pharmacokinetic Trial of Patupilone Combined with Carboplatin in Patients with Advanced Cancer
Forster, M. D., Kaye, S. B., Oza, A. M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1653 · Cited by 31
“The taxanes paclitaxel and docetaxel inhibit cell proliferation by stabilizing microtubule dynamics, thereby inducing aberrant spindle formation during mitosis, mitotic cell-cycle arrest, and apoptotic cell death (1).”
Background
Design and synthesis of pironetin analogue/combretastatin A-4 hybrids containing a 1,2,3-triazole ring and evaluation of their cytotoxic activity
Vilanova, C., Torijano‐Gutiérrez, S., Díaz‐Oltra, S., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.053 · Cited by 31
Cytostatic Activity of Paclitaxel in Coronary Artery Smooth Muscle Cells is Mediated Through Transient Mitotic Arrest Followed by Permanent Post-Mitotic Arrest: Comparison with Cancer Cells
Blagosklonny, M. V., Demidenko, Z. N., Giovino, M. A., et al. (2006) · Cell Cycle · doi:10.4161/cc.5.14.3113 · Cited by 31
The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration
Prell, R. A., Gearin, L., Simmons, A. D., VanRoey, M. J., & Jooss, K. U. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0116-4 · Cited by 31
“Its primary mechanism of action is via increasing tubulin polymerization and microtubule assembly and inhibiting tubulin depolymerization, resulting in cell cycle arrest at the G2/M interface [6–9].”
Background
circRNAs in drug resistance of breast cancer
Mısır, S., Yaman, S. Ö., Petrović, N., Sümer, C., Hepokur, C., & Aliyazıcıoğlu, Y. (2022) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2022.027547 · Cited by 31
Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel
Chang, C.-C., Liang, Y., Klutz, A. M., et al. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0214-9 · Cited by 30
“Paclitaxel, a taxane, interferes with the depolymerization of microtubules, causing cell cycle arrest in mitosis and subsequent induction of apoptosis [3].”
Background
Cell death and cytotoxic effects in YAC-1 lymphoma cells following exposure to various forms of mercury
Yole, M., Wickstrom, M. L., & Blakley, B. R. (2006) · Toxicology · doi:10.1016/j.tox.2006.11.062 · Cited by 30
Multimodality Imaging Review of HER2-positive Breast Cancer and Response to Neoadjuvant Chemotherapy
Portnow, L. H., Kochkodan-Self, J., Maduram, A., et al. (2023) · Radiographics · doi:10.1148/rg.220103 · Cited by 29
Tubulin binding cofactor C (TBCC) suppresses tumor growth and enhances chemosensitivity in human breast cancer cells
Hage‐Sleiman, R., Herveau, S., Matera, E., Laurier, J.-F., & Dumontet, C. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-135 · Cited by 28
“lateral polymerization and suppresses microtubule dynamics [ 45 ].”
Background
In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway– and microtubule-targeting inhibitors
Skobeleva, N., Menon, S., Weber, L., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0602 · Cited by 29
“Induction of cell death by microtubule-targeting agents is most potent when treated cells are in mitosis (32, 33).”
Background
The Role of p27 Kip1 in Dasatinib-Enhanced Paclitaxel Cytotoxicity in Human Ovarian Cancer Cells
Le, X., Mao, W., He, G., Claret, F.-X., Xia, W., Ahmed, A. A., Hung, M., Siddik, Z. H., & Bast, R. C. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr280 · Cited by 28
“Mitotic slippage is well known to induce a multinucleated phenotype (54,55) and postmitotic cell death (54,56,57).”
Current Research and Development of Chemotherapeutic Agents for Melanoma
Hsan, K. M., Chen, C., & Shyur, L. (2010) · Cancers · doi:10.3390/cancers2020397 · Cited by 27
“These compounds can bind with tubulin and thus prevent the formation of microtubules [29].”
Background
212Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint
Yong, K. J., Milenic, D. E., Baidoo, K. E., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.189 · Cited by 28
“The resultant mitotic arrest triggers rapid onset of the p53-independent apoptotic pathway (Abal et al, 2003).”
Background
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds
Tagliamento, M., Genova, C., Rossi, G., Coco, S., Rijavec, E., Bello, M. G. D., Boccardo, S., Grossi, F., & Alama, A. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1627326 · Cited by 29
“to anaphase, resulting in mitotic arrest and subsequent apoptosis [11,12].”
Background
Targeting the Microtubular Network as a New Antimyeloma Strategy
Feng, R., Li, S., Lu, C., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0234 · Cited by 28
“The coordinatedprocesses of cell-cycle progression, cell growth, and apoptosis are dysfunctional in cancer (1, 2).”
Background
Paclitaxel-related balloons and stents for the treatment of peripheral artery disease: Insights from the Food and Drug Administration 2019 Circulatory System Devices Panel Meeting on late mortality
Dan, K., Shlofmitz, E., Khalid, N. M., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.12.012 · Cited by 27
A look into the link between centrosome amplification and breast cancer
Zhang, Y., Tian, J., Qu, C., Peng, Y., Lei, J., Sun, L., Zong, B., & Liu, S. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110924 · Cited by 28
Breaking Tolerance in a Mouse Model of Multiple Myeloma by Chemoimmunotherapy
Sharabi, A., & Haran‐Ghera, N. (2010) · Advances in cancer research · doi:10.1016/s0065-230x(10)07001-6 · Cited by 27
Fluorescent Taxoid Probes for Microtubule Research
Barasoaı́n, I., Díaz, J. F., & Andreu, J. M. (2010) · Methods in cell biology · doi:10.1016/s0091-679x(10)95019-x · Cited by 27
Self-citation
Enhancement of Docetaxel-Induced Cytotoxicity by Blocking Epidermal Growth Factor Receptor and Cyclooxygenase-2 Pathways in Squamous Cell Carcinoma of the Head and Neck
Choe, M. S., Chen, Z., Klass, C. M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2959 · Cited by 27
Adjuvant effect of docetaxel on the immune responses to influenza A H1N1 vaccine in mice
Chen, J., Yuan, L., Fan, Q., et al. (2012) · BMC Immunology · doi:10.1186/1471-2172-13-36 · Cited by 26
“At the late 1970s, paclitaxel was discovered able to blocks mitosis and cause the death of cancer cells by binding to and stabilizing microtubules [16,17].”
Background
Sodium Selenite Decreased HDAC Activity, Cell Proliferation and Induced Apoptosis in Three Human Glioblastoma Cells
Hazane‐Puch, F., Arnaud, J., Trocmé, C., Faure, P., Laporte, F., & Champelovier, P. (2016) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520615666150819095426 · Cited by 26
Loss of EGFR induced autophagy sensitizes hormone refractory prostate cancer cells to adriamycin
Xu, S., & Weihua, Z. (2011) · The Prostate · doi:10.1002/pros.21337 · Cited by 26
Cytotoxicity of Docetaxel (Taxotere®) Used as a Single Agent and in Combination with Radiation in Human Gastric, Cervical and Pancreatic Cancer Cells
Balcer‐Kubiczek, E. K., Attarpour, M., Jiang, J., Kennedy, A. S., & Suntharalingam, M. (2006) · Chemotherapy · doi:10.1159/000094869 · Cited by 26
A review on integrative approaches in oncology: bridging ayurvedic medicine and modern cancer therapeutics
Jha, S. K., Singh, N., Shanker, O. R., Antil, I., Baghel, J. S., Huddar, V. G., & Tripathi, R. (2025) · Frontiers in Natural Products · doi:10.3389/fntpr.2025.1635197 · Cited by 29
RETRACTED: Globularifolin exerts anticancer effects on glioma U87 cells through inhibition of Akt/mTOR and MEK/ERK signaling pathways in vitro and inhibits tumor growth in vivo
Yu, Y., Fu, X., Ran, Q., Yang, K., Wen, Y., Li, H., & Wang, F. (2017) · Biochimie · doi:10.1016/j.biochi.2017.09.005 · Cited by 25
Retracted
Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms
Legrier, M.-E., Oudard, S. M., Judde, J.-G., Guyader, C., Pinieux, G. D. B. D., Boyé, K., de Crémoux, P., Dutrillaux, B., & Poupon, M. F. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603553 · Cited by 25
“Taxanes block tubulin depolymerisation, resulting in impairment of cellular mitosis (Horwitz, 1994), generating nuclear abnormalities and multipolar divisions, ultimately leading to cell death (Abal et al, 2003).”
Background
Sites of biosynthesis and storage of Taxol in Taxus media (Rehder) plants: Mechanism of accumulation
Soliman, S. S. M., & Raizada, M. N. (2020) · Phytochemistry · doi:10.1016/j.phytochem.2020.112369 · Cited by 24
Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers
Alhusaini, A., Cannon, A., Maher, S. G., Reynolds, J. V., & Lynam-Lennon, N. (2021) · Biomedicines · doi:10.3390/biomedicines9081024 · Cited by 24
“The primary mechanism of anti-microtubule agents is to halt tumour cell mitosis by disrupting microtubule function [147,148].”
Background
Synthesis and biological evaluation of novel anticancer bivalent colchicine–tubulizine hybrids
Malysheva, Y. B., Combes, S., Allegro, D., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.05.072 · Cited by 24
Decrease in c-Myc activity enhances cancer cell sensitivity to vinblastine
Bressin, C. L., Bourgarel‐Rey, V., Carr??, M., Pourroy, B., Arango, D., Braguer, D., & Barra, Y. (2006) · Anti-Cancer Drugs · doi:10.1097/00001813-200602000-00009 · Cited by 24
3′-Deoxy-3′-[18F]fluorothymidine (FLT) uptake in breast cancer cells as a measure of proliferation after doxorubicin and docetaxel treatment
Dittmann, H., Jusufoska, A., Dohmen, B. M., Smyczek-Gargya, B., Fersis, N., Pritzkow, M., Kehlbach, R., Vonthein, R., Machulla, H.-J., & Bares, R. (2009) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2008.10.012 · Cited by 24
Paclitaxel/Luteolin Coloaded Dual‐Functional Liposomes for Esophageal Cancer Therapy
Sun, C., Xie, F., Zhang, H., Feng, L., Wang, Y., Huang, C., Cui, Z., Luo, C., Zhang, L., & Wang, Q. (2025) · Advanced Science · doi:10.1002/advs.202411930 · Cited by 25
Complications from pharmacotherapy
Nabors, B., Surboeck, B., & Grisold, W. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00014-1 · Cited by 23
MicroRNAs: key players of taxane resistance and their therapeutic potential in human cancers
Cui, S., Wang, R., & Chen, L. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12131 · Cited by 25
“They both inhibit the process of cell division, causing a ‘frozen mitosis’ by stabilizing microtubules and thus preventing disassembly [7].”
Background
Drug-Eluting Stent - Importance of Clinico-Pathological Correlations -
Hao, H., Ishibashi‐Ueda, H., Tsujimoto, M., et al. (2011) · Circulation Journal · doi:10.1253/circj.cj-11-0393 · Cited by 22
A gene expression signature in HER2+ breast cancer patients related to neoadjuvant chemotherapy resistance, overall survival, and disease-free survival
Barrón-Gallardo, C. A., García‐Chagollán, M., Morán-Mendoza, A. J., Delgadillo-Cristerna, R., Martínez-Silva, M. G., Villaseñor-Garcı́a, M. M., Aguilar‐Lemarroy, A., & Jave‐Suárez, L. F. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.991706 · Cited by 22
“The treatment of HER2+ breast cancer includes the administration of chemotherapy and trastuzumab, a monoclonal antibody against the HER2 receptor (Abal et al., 2003; Harbeck and Gnant, 2017; Waks and Winer, 2019).”
Background
Novel triazole analogs of apigenin‑7‑methyl ether exhibit potent antitumor activity against ovarian carcinoma cells via the induction of mitochondrial‑mediated apoptosis
Qi, Y., Ding, Z., Yao, Y., et al. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.7138 · Cited by 22
Retracted
Cyclin-dependent kinase 1-mediated AMPK phosphorylation regulates chromosome alignment and mitotic progression
Stauffer, S., Zeng, Y., Santos, M., Zhou, J., Chen, Y., & Dong, J. (2019) · Journal of Cell Science · doi:10.1242/jcs.236000 · Cited by 25
“, 2011) or through aberrant mitosis and eventual death in G1 (Abal et al., 2003).”
Background
Fluorocopolymer-coated nitinol self-expanding paclitaxel-eluting stent: pharmacokinetics and vascular biology responses in a porcine iliofemoral model
Hou, D., Huibregtse, B. A., Eppihimer, M. J., et al. (2016) · EuroIntervention · doi:10.4244/eijv12i6a128 · Cited by 22
Targeting synuclein-γ to counteract drug resistance in cancer
Singh, V. K., & Jia, Z. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.1.59 · Cited by 21
“These microtubule-disrupting agents are thought to arrest cells in mitosis by triggering spindle assembly checkpoint activation, this results in the cells being arrested in the mitotic phase without entering anaphase ( Figure 2 ) [60-62] .”
Background
Synergistic Anticancer Effect of Peptide‐Docetaxel Nanoassembly Targeted to Tubulin: Toward Development of Dual Warhead Containing Nanomedicine
Mohapatra, S., Saha, A., Mondal, P., Jana, B., Ghosh, S., Biswas, A., & Ghosh, S. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201600718 · Cited by 20
Impact of Docetaxel on blood-brain barrier function and formation of breast cancer brain metastases
Bernatz, S., Ilina, E. I., Devraj, K., Harter, P. N., Mueller, K. M., Kleber, S., Braun, Y., Penski, C., Renner, C., Halder, R., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1427-1 · Cited by 19
“Furthermore, taxanes induce apoptosis, however the underlying mechanisms are not yet fully understood [18, 19].”
Background
A Review of Treatment-Induced Pulmonary Toxicity in Breast Cancer
Mo, H., Jazieh, K., Brinzevich, D., & Abraham, J. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.05.014 · Cited by 21
Mitogenic Action of the Androgen Receptor Sensitizes Prostate Cancer Cells to Taxane-Based Cytotoxic Insult
Hess-Wilson, J. K., Daly, H. K., Zagórski, W., Montville, C. P., & Knudsen, K. E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2249 · Cited by 21
“It has been hypothesized that the ability of paclitaxel to interfere with cytokinesis would make dividing cells more sensitive; however, there has been significant variation in cellular sensitivity to paclitaxel (46).”
Background
Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention
Perez, A. M., Haberland, N. I., Miteva, M. I., et al. (2024) · Current Oncology · doi:10.3390/curroncol31090423 · Cited by 20
“Because taxanes initiate tumor cell death by directly interfering with the cell cycle, the ability to arrest the HF cell cycle makes the HFs less susceptible to taxane-induced damage in CIA [35,66,75–80].”
Background
Expulsion of iron-rich ferritin via CD63-mediated exosome drives ferroptosis resistance in ovarian cancer cells
Battaglia, A. M., Sacco, A., Giorgio, E., Petriaggi, L., Elzanowska, J., Cruz, A. R., Rocha, L., Pereira, C. E., Moraes, M. C. S., Palazzo, L., et al. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1532097 · Cited by 21
Novel application of drug-coated balloons in coronary heart disease: A narrative review
Wang, L., Li, X., Li, T. X., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1055274 · Cited by 20
Synthesis and biological evaluation of truncated α-tubulin-binding pironetin analogues lacking alkyl pendants in the side chain or the dihydropyrone ring
Paños, J., Díaz‐Oltra, S., Sánchez‐Peris, M., García-Pla, J., Murga, J., Falomir, E., Cardá, M., Redondo‐Horcajo, M., Díaz, J. F., Barasoaı́n, I., et al. (2013) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob40854j · Cited by 20
Self-citation
High expression of TIMP-1 in human breast cancer tissues is a predictive of resistance to paclitaxel-based chemotherapy
Zhu, D., Zha, X., Hu, M., Tao, A.-D., Zhou, H., Zhou, X., & Sun, Y. (2012) · Medical Oncology · doi:10.1007/s12032-012-0239-3 · Cited by 20
“Paclitaxel can bind tubulin to promote tubulin polymerization and block depolymerization of microtubules, thereby disrupting dynamic balance of tubulin polymerization/depolymerization and spindle function, inhibiting mitosis to block cells in G2/M phase, ultimately leading to apoptosis [10, 11].”
Background
Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation.
Maráz, A., Furák, J., Pálföldi, R., et al. (2011) · PubMed · Cited by 20
Selective Killing of Adriamycin-Resistant (G2 Checkpoint-Deficient and MRP1-Expressing) Cancer Cells by Docetaxel
Demidenko, Z. N., Halicka, D. H., Kunicki, J., McCubrey, J. A., Darżynkiewicz, Z., & Blagosklonny, M. V. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4428 · Cited by 20
Ferroptosis: a novel strategy to overcome chemoresistance in gynecological malignancies
Xu, J., Zheng, B., Wang, W., & Zhou, S. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1417750 · Cited by 26
Taxanes in the Treatment of Advanced Gastric Cancer
Kang, B., Kwon, O., Chung, H. Y., Yu, W., & Kim, J. G. (2016) · Molecules · doi:10.3390/molecules21050651 · Cited by 19
“As their name suggests, taxanes were first derived from natural sources, yet now are synthesized artificially (Table 1) [16].”
Background
Paclitaxel inhibits osteoclast formation and bone resorption via influencing mitotic cell cycle arrest and RANKL‐induced activation of NF‐κB and ERK
Ang, E. S. M., Pavlos, N. J., Chim, S. M., Feng, H., Scaife, R. M., Steer, J. H., Zheng, M., & Xu, J. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23423 · Cited by 19
“Bars, 20mm. 952 EFFECTS OF PACLITAXEL ON OSTEOCLASTS JOURNAL OF CELLULAR BIOCHEMISTRY Previous studies have shown that paclitaxel binds to b-tubulin and inhibits microtubule dynamic instability, leading to apoptosis in several cell types [Abal et al., 2003; Bhalla, 2003].”
BackgroundInfluential
Cell cycle‐tailored targeting of metastatic melanoma: Challenges and opportunities
Haass, N. K., & Gabrielli, B. G. (2017) · Experimental Dermatology · doi:10.1111/exd.13303 · Cited by 20
Drug-Eluting Stent Shows Similar Patency Results as Prosthetic Bypass in Patients with Femoropopliteal Occlusion in a Randomized Trial
Björkman, P., Auvinen, T., Hakovirta, H. H., et al. (2018) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2018.04.014 · Cited by 19
Less Is More: Developments in Nanotechnology for Antirestenosis Therapies
Trepanier, C. M., Burke‐Kleinman, J., Strauss, B. H., Santerre, J. P., & Bendeck, M. P. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.318450 · Cited by 19
Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to paclitaxel
Zhao, W., Song, Y., Xu, B., et al. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.13.3.18697 · Cited by 18
“Paclitaxel blocks cells in the G2-M phase of the cell cycle and such cells are unable to form a normal mitotic apparatus and then undergo apoptosis.(39,40) Figure 3.”
Background
DES Design: Theoretical Advantages and Disadvantages of Stent Strut Materials, Design, Thickness, and Surface Characteristics
Bailey, S. R. (2009) · Journal of Interventional Cardiology · doi:10.1111/j.1540-8183.2009.00449.x · Cited by 18

Authors: Abal, M., Andreu, J., & Barasoain, I.
Affiliations: Centre National de la Recherche Scientifique (FR)
ORCID: Abal, M.
Andreu, J.
Venue: Current Cancer Drug Targets
Publisher: Bentham Science Publishers Ltd.
Published: 2003-06-01
Volume: 3
Issue: 3
Pages: 193-203
ISSN: 1568-0096 (ISSN-L)
DOI: 10.2174/1568009033481967
OpenAlex: W2164778107
Cited by: 383
References: 0
Citations by year: 2026: 7 · 2025: 14 · 2024: 18 · 2023: 21 · 2022: 22 · 2021: 22 · 2020: 14 · 2019: 19 · 2018: 22 · 2017: 21 · 2016: 23 · 2015: 11 · 2014: 22 · 2013: 14 · 2012: 16
FWCI: 5.35
Type: journal article
Language: en
Open access: closed
Locations: Current Cancer Drug Targets (publishedVersion)
PubMed (publishedVersion)
DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
Funders: Fundación Científica Asociación Española Contra el Cáncer
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
Keywords: taxanes, paclitaxel, microtubules, centrosome, spindle microtubules, mitosis, mitotic slippage, apoptosis, Bcl-2 phosphorylation, p53, taxane resistance, cell cycle checkpoints, antimitotic agents
MeSH terms: Animals, Cell Cycle, Humans, Microtubules, Drug Delivery Systems, Paclitaxel, Centrosome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Taxanes: Microtubule and Centrosome Targets, and Cell Cycle Dependent Mechanisms of Action

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks